Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic Semaglutide Sun Pharmaceutical, Dr. Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals launched generic versions of Semaglutide on March 21, 2026, following the expiration of the patent for the active ingredient in Novo Nordisk’s diabetes and weight loss drugs, Wegovy and Ozempic, in India. This marked the entry of several pharmaceutical companies into the market, with Natco Pharma and its partner Eris Lifesciences having already announced their product availability on March 20, the day before the patent expired. The move is expected to open up a $1 billion market for Semaglutide in India over the next few years, driven by the growing prevalence of diabetes and pre-diabetes. The companies are positioning their generic versions as cost-effective alternatives to the branded drugs, which are typically priced much higher. Semaglutide, a GLP-1 receptor agonist, is used to treat type 2 diabetes and obesity. Dr. Reddy’s Laboratories introduced its Semaglutide injection, branded as Obeda, in 2 mg and 4 mg strengths. The product is available in a pre-filled, disposable pen for once-a-week subcutaneous administration, with a monthly cost of ₹4,200 for both strengths. The company’s leadership team highlighted the product’s user-friendly design and its potential for approval for weight management in the near future. Sun Pharmaceutical launched its Semaglutide injections under the brand names Noveltreat and Sematrinity. Noveltreat, intended for chronic weight management, ranges from ₹900 to ₹2,000 per month, while Sematrinity, for type 2 diabetes, costs between ₹750 and ₹1,300. Zydus Life Sciences introduced Semaglutide under the brands Semaglyn, Mashema, and Alterme, with an average monthly cost of ₹2,200.#novartis #sun_pharma #dr_reddy_s_laboratories #zydus_life_sciences #glenmark_pharmaceuticals
Accenture Expands AI Faculty with Acquisition of UK-Based Firm Accenture has announced the acquisition of UK-based AI firm Faculty, a move that enhances its capabilities in delivering company transformation services through advanced technology and expertise. The acquisition, which was finalized with an undisclosed financial agreement, is expected to position Accenture as a leader in helping clients adopt AI solutions effectively. Accenture’s CEO, Julie Sweet, highlighted the strategic importance of the acquisition, emphasizing that it strengthens the company’s ability to provide critical technology and expertise required to capitalize on AI advancements. She noted that the integration of Faculty’s capabilities will enable Accenture to offer more tailored solutions to its clients, particularly in areas where AI implementation is complex and requires specialized knowledge. A key aspect of the deal is the appointment of Dr. Marc Warner, Faculty’s co-founder and CEO, as Accenture’s Chief Technology Officer and a member of its Global Management Committee. Warner, who has been instrumental in developing Faculty’s AI technologies, will play a pivotal role in shaping Accenture’s future strategies in the AI space. The acquisition also includes the integration of over 400 “AI-native professionals” from Faculty, including highly qualified data scientists and engineers. Accenture described the team as “PhD-heavy,” with expertise in developing AI systems for both public and private-sector organizations across the UK and globally. This influx of talent is expected to bolster Accenture’s research and development efforts, enabling the company to address a broader range of AI challenges. Faculty’s flagship product, Frontier, is a unified system that connects data, AI models, and business processes to streamline decision-making.#accenture #julie_sweet #faculty #dr_marc_warner #novartis
